Top 10 Healthcare vs Food Companies by Revenue in 2025: Revenue, Market Cap Comparisons, ETF Insights, and Performance Analysis

In 2025, the healthcare and food industries remain pivotal to the global economy, navigating challenges such as inflation, supply chain issues, and sustainability demands. Healthcare leaders emphasize insurance, pharmaceuticals, and services, while food companies focus on production, retail, and consumer trends. This updated article merges rankings from key sources, incorporating market capitalization data as of November 2025 for comprehensive comparisons. 

Based on 2024-2025 trailing twelve-month (TTM) and fiscal year revenues, we present the top companies in each sector, now in list format, including Eli Lilly due to its significant presence and high market valuation despite not ranking in the original top 10 by revenue. We've also incorporated related ETFs as of November 2025, with a focus on pharmaceutical ETFs integrated into the healthcare section. Ideal for investors, professionals, and enthusiasts tracking economic giants.

Top Healthcare Companies by Revenue in 2025The healthcare sector's revenues have surged due to expansions, acquisitions, and tech innovations. Below is a list comparing revenue and market capitalization (as of November 2025).

1. UnitedHealth Group Inc. (UNH): Revenue ~$400 billion, Market Cap $290 billion
   Leading insurer with data analytics and pharmacy services. Traded on NYSE.
2. CVS Health Corp. (CVS): Revenue $361-373 billion, Market Cap $99 billion
   Pharmacy benefits manager; undervalued with strong YTD performance.
3. McKesson Corp. (MCK): Revenue $309-359 billion, Market Cap $107 billion
   Global pharmaceutical distribution and services.
4. Cencora (formerly AmerisourceBergen) (COR): Revenue $294-310 billion, Market Cap $71 billion
   Pharmaceutical sourcing and distribution.
5. Cardinal Health Inc. (CAH): Revenue $220-227 billion, Market Cap $50 billion
   Manufacturer and distributor of medical products.
6. Cigna Group (CI): Revenue $204-247 billion, Market Cap $74 billion
   Global health services in over 30 countries.
7. Elevance Health (formerly Anthem) (ELV): Revenue $172-177 billion, Market Cap $72 billion
   Health plans and complex-care products.
8. Johnson & Johnson (JNJ): Revenue $88.8 billion, Market Cap $491 billion
   Focuses on innovative medicines; projected 5-7% annual growth through 2030.
9. Sinopharm Group (SHTDY): Revenue $80 billion, Market Cap $8 billion
   Listed on Hong Kong Exchange; considered undervalued.
10. Roche Holding (RHHBY): Revenue $73.6 billion, Market Cap $313 billion
    Q1 2025 sales up 6%; key product Vabysmo hit $4.5B in 2024.

Notable Addition: Eli Lilly and Company (LLY): Revenue $59.42 billion (TTM), Market Cap $948.45 billion. Pharmaceutical leader known for innovations in diabetes and weight loss treatments. Included for its standout market valuation, reflecting strong investor confidence in growth potential.Totals (including Eli Lilly): Revenue ~$2,161-2,310 billion, Market Cap $2,523 billionTop 10 Food Companies by Revenue in 2025The food industry adapts to health and sustainability trends, with resilient global operations. See the revenue and market cap comparison list below (market caps as of November 2025).

1. Nestlé (Switzerland) (NSRGY): Revenue $113 billion, Market Cap $257 billion
   World's largest food manufacturer; brands include Nescafe, KitKat, and Purina. Operates in 188 countries.
2. Ahold Delhaize (Netherlands) (ADRNY): Revenue $96.22 billion, Market Cap $37 billion
   Major global retailer and distributor.
3. PepsiCo (USA) (PEP): Revenue $91.52 billion, Market Cap $200 billion
   Beverages and snacks leader; acquired Siete Foods for $1.2B in January 2025.
4. Archer Daniels Midland (ADM) (USA): Revenue $85.53 billion, Market Cap $28 billion
   Largest agricultural processors and ingredient providers.
5. Sysco Corporation (USA) (SYY): Revenue $80.57 billion, Market Cap $37 billion
   Leading global foodservice distribution.
6. Performance Food Group (USA) (PFGC): Revenue $60.10 billion, Market Cap $15 billion
   Foodservice distributor with broad range.
7. Anheuser-Busch InBev (Belgium) (BUD): Revenue $59.76 billion, Market Cap $122 billion
   World's largest brewer with global brands.
8. Unilever (UK/Netherlands) (UL): Revenue $58.20 billion, Market Cap $148 billion
   Diversified in food and personal care; brands like Magnum and Knorr.
9. Tyson Foods (USA) (TSN): Revenue $53.61 billion, Market Cap $19 billion
   Major meat producer in poultry, beef, and pork.
10. Bunge Limited (USA) (BG): Revenue $53.10 billion, Market Cap $18 billion
    Agribusiness and food ingredient company.

Totals: Revenue ~$851 billion, Market Cap $881 billionTop ETFs Related to Healthcare and Food Sectors in 2025As of November 2025, these ETFs provide diversified exposure to the sectors. The healthcare list includes pharmaceutical and biotech-focused ETFs for targeted pharma exposure. Rankings are by assets under management (AUM) in billions of USD, with year-to-date (YTD) and 3-month returns for context.Top Healthcare ETFs (Including Pharma/Biotech)

1. Health Care Select Sector SPDR Fund (XLV): AUM $39.01 billion, YTD Return 12.39%, 3-Month Return 13.52%
   Broad healthcare exposure including major companies like UnitedHealth and Johnson & Johnson.
2. Vanguard Health Care ETF (VHT): AUM $16.86 billion, YTD Return 13.44%, 3-Month Return 13.91%
   Tracks MSCI US Investable Market Health Care 25/50 Index.
3. iShares Biotechnology ETF (IBB): AUM $8.10 billion, YTD Return 26.71%, 3-Month Return 22.21%
   Focuses on biotech firms, a key pharma subsector.
4. State Street SPDR S&P Biotech ETF (XBI): AUM $7.41 billion, YTD Return 29.52%, 3-Month Return 31.38%
   Equal-weighted biotech, emphasizing innovative pharma.
5. VanEck Pharmaceutical ETF (PPH): AUM $1.16 billion, YTD Return 18.06%, 3-Month Return ~8% (recent surge)
   Targets global pharmaceutical companies like Eli Lilly and Johnson & Johnson.
6. iShares U.S. Pharmaceuticals ETF (IHE): AUM $0.68 billion, YTD Return ~18% (estimated based on surges), 3-Month Return ~8%
   U.S.-focused pharma, including Merck and Pfizer.
7. iShares Global Healthcare ETF (IXJ): AUM $4.30 billion, YTD Return 12.66%, 3-Month Return 11.21%
   Global healthcare, including pharma giants like Roche.
8. iShares U.S. Medical Devices ETF (IHI): AUM $4.11 billion, YTD Return 7.46%, 3-Month Return 1.10%
   Medical devices complementing pharma.
9. iShares U.S. Healthcare ETF (IYH): AUM $3.33 billion, YTD Return 11.69%, 3-Month Return 13.42%
   Broad U.S. healthcare.
10. Invesco Pharmaceuticals ETF (PJP): AUM $0.30 billion, YTD Return 18.21%, 3-Month Return ~8.7%
    Dynamic pharma selection, including AbbVie and Gilead.

Top Food and Beverage/Consumer Staples ETFs

1. Consumer Staples Select Sector SPDR Fund (XLP): AUM $14.94 billion, YTD Return -0.90%, 3-Month Return -3.90%
   Core staples like Procter & Gamble and Coca-Cola.
2. Vanguard Consumer Staples ETF (VDC): AUM $7.11 billion, YTD Return 0.28%, 3-Month Return -3.33%
   Broad staples exposure.
3. Fidelity MSCI Consumer Staples Index ETF (FSTA): AUM $1.29 billion, YTD Return -0.06%, 3-Month Return -3.40%
   Tracks MSCI USA IMI Consumer Staples.
4. iShares U.S. Consumer Staples ETF (IYK): AUM $1.29 billion, YTD Return 4.80%, 3-Month Return -2.23%
   U.S. staples with some healthcare tilt.
5. iShares Global Consumer Staples ETF (KXI): AUM $0.87 billion, YTD Return 7.83%, 3-Month Return -1.04%
   Global view including Nestlé and Unilever.
6. VanEck Agribusiness ETF (MOO): AUM $0.56 billion, YTD Return 10.03%, 3-Month Return -5.99%
   Agribusiness linked to food production.
7. Invesco Food & Beverage ETF (PBJ): AUM $0.10 billion, YTD Return -4.93%, 3-Month Return -7.67%
   Dynamic food and beverage.
8. Invesco Dorsey Wright Consumer Staples Momentum ETF (PSL): AUM $0.08 billion, YTD Return -5.48%, 3-Month Return -11.63%
   Momentum-based staples.
9. Invesco S&P SmallCap Consumer Staples ETF (PSCC): AUM $0.03 billion, YTD Return -18.36%, 3-Month Return -11.86%
   Small-cap staples.
10. First Trust Nasdaq Food & Beverage ETF (FTXG): AUM $0.02 billion, YTD Return -7.06%, 3-Month Return -5.74%
    Nasdaq-focused food and beverage.

Market Cap Comparisons, Performance Analysis, and Industry Insights for 2025Comparing the sectors, healthcare's companies (including Eli Lilly) boast a total market cap of approximately $2,523 billion, significantly higher than the food sector's $881 billion, despite healthcare's aggregate revenues ($2,161-2,310B) being roughly 2.5 times food's ($851B). This disparity highlights investor confidence in healthcare's growth potential, driven by demographics and innovation, versus food's maturity and margin pressures. Notably, Eli Lilly's $948B market cap is the highest in the healthcare list, surpassing even Johnson & Johnson's $491B, despite its lower revenue—reflecting excitement around its pharmaceutical advancements. For instance, Johnson & Johnson's cap dwarfs its $89B revenue, while PepsiCo's $200B aligns closely with its $92B in consumer goods.
Analyzing performance, healthcare companies and ETFs have outperformed food/consumer staples counterparts in 2025. Healthcare ETFs show strong YTD returns, averaging 12-29% (e.g., XLV at 12.39%, XBI at 29.52%), bolstered by pharma and biotech surges amid Q3 earnings beats and AI integration in drug development. Pharma-specific ETFs like PPH (18.06%) and PJP (18.21%) reflect robust sector momentum, with recent monthly gains of 7-9% following strong results from holdings like Eli Lilly. In contrast, food/consumer staples ETFs are mostly flat or negative, with XLP at -0.90% YTD and others down to -18%, impacted by cost pressures and defensive underperformance in a risk-on market. Sector-wide, healthcare's YTD gains (e.g., 4-12% through late 2025) outpace staples' minimal or negative returns (0-3% or lower), underscoring healthcare's resilience and growth amid economic uncertainty.
Both industries grapple with 3.9% global inflation and sustainability goals—e.g., Nestlé's 91.9% renewable energy usage. Exclusions like private Cargill ($165B revenue) or McDonald's (~$25-26B) underscore focus on top public players. Watch for 2026 shifts from acquisitions like PepsiCo's deals. 
Data sourced from financial reports and market analyses.

Disclaimer

The information presented in this article is intended for general informational purposes only and should not be construed as professional financial, investment, or medical advice. The revenue figures, company rankings, and projections are based on publicly available data, company reports, and industry estimates as of 2025. All currency conversions, where applicable, are based on annual average exchange rates.

While efforts have been made to ensure the accuracy and timeliness of the information, One Day Advisor and the article’s authors do not guarantee the completeness, reliability, or suitability of the content for any particular purpose. Readers are encouraged to verify details independently and consult qualified professionals before making any business, investment, or healthcare decisions based on the information provided.

The article may reference ongoing developments, regulatory actions, or market events that are subject to change. One Day Advisor is not responsible for any losses or damages arising from the use of this information.

References and Sources:

• https://www.onedayadvisor.com/2025/06/top-10-healthcare-companies-by-revenue.html

• https://www.onedayadvisor.com/2025/07/top-10-pharma-companies-by-market-cap.html

• https://www.onedayadvisor.com/2025/06/top-10-drugs-losing-US-exclusivity.html

• https://www.onedayadvisor.com/2025/06/top-10-most-anticipated-drug-launches.html

• https://www.onedayadvisor.com/2025/06/top-10-pharmaceutical-companies-by.html